As of November, around one in eight adults in the US say they are currently taking a GLP-1 drug, whether for weight loss or another chronic condition. That is a remarkable adoption curve for a class of medicines that, until recently, sat largely inside diabetes care. It also explains why big pharma is moving fast,aaa
Read more